Welcome to our dedicated page for Cardiac Biotech Solutions news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cardiac Biotech Solutions stock.
Cardiac Biotech Solutions, Inc. (CBSC) is a medical technology company that regularly issues news updates about its non-invasive ambulatory cardiac monitoring products, regulatory milestones, and international distribution activities. Its disclosures focus on the MyCardia AT and CardioHolter AT cardiac event monitoring platforms, which combine wearable devices with AWS Cloud-based connectivity and mobile applications.
News coverage for CBSC often highlights regulatory approvals and submissions, such as FDA clearance for MyCardia AT in the United States and a Medical Device License from Health Canada for the CardioHolter AT in Canada. The company also reports on progress toward regulatory clearance in China through collaborations with licensed NMPA medical device manufacturers and hospital-based clinical field testing.
Investors and healthcare observers following CBSC’s news can expect announcements about distribution agreements and purchase orders in key markets. Recent releases have described exclusive distribution arrangements with partners in Canada, Central America, and South America, as well as initial purchase orders for thousands of devices that support the company’s combined device sales and recurring rental revenue model.
Additional CBSC news items address corporate developments, including the company’s name change from CB Scientific, Inc. to Cardiac Biotech Solutions, Inc., voluntary delisting from the OTCQB Venture Market while continuing to trade on the OTC Pink Open Market, and updates on financing efforts and technology initiatives. For readers interested in how remote cardiac monitoring technologies are being deployed across multiple regions and regulatory environments, the CBSC news feed provides ongoing insight into the company’s product launches, partnerships, and strategic steps in the ambulatory cardiac monitoring space.
CB Scientific (OTC PINK:CBSC) has announced a partnership with Shenzhen Pump Medical System Co., Ltd. to manufacture medical products aimed at the Southeast Asian market. This collaboration is crucial for establishing local manufacturing capabilities and securing necessary FDA and NMPA approvals. CEO Charles Martin emphasized the importance of this relationship for regulatory validation and gaining access to regional distribution channels. The company plans to provide updates on future developments to shareholders and the public.
CB Scientific Inc. (OTC PINK:CBSC) announced a Special Stockholder Meeting to approve enhancements aimed at positioning the company for growth. The meeting will address a corporate name change, relocation for tax advantages, increased authorized shares for fundraising, and a ratification of the 2021 Omnibus Stock Incentive Plan. Management believes recent progress in Southeast Asia and an application to up list to the OTCQB creates the momentum needed for these changes. Details on the meeting date will be provided in the coming weeks.
CB Scientific (OTC PINK:CBSC) announced its application for uplisting to the OTCQB Venture Market. This move is aimed at enhancing trading efficiency and transparency. While the submission does not guarantee acceptance, the company has completed necessary steps, including a PCAOB audit and appointing independent directors. CEO Charles Martin emphasized that uplisting would position CBSC better for future goals, including a potential shift to Nasdaq. The company anticipates that uplisting will lead to improved compliance, reporting standards, and analyst coverage.
CB Scientific Inc. (OTC PINK:CBSC) has appointed Brooke Martellaro as its new Chief Financial Officer, effective immediately. Martellaro brings extensive experience from various corporations, enhancing the company's executive management. Her immediate focus includes collaborating with MaloneBailey LLP to conclude a PCAOB audit, vital for CBSC’s transition to the OTCQB Venture Market. The company emphasizes that Martellaro's financial expertise will significantly contribute to strategic and operational improvements, facilitating long-term success.
CB Scientific has appointed Paul K. Danner as Chairman of its Board of Directors, effective immediately. Danner brings over 25 years of experience with Nasdaq-listed companies. His leadership aims to enhance the company’s executive team amid plans for a timely uplist to the OTCQB Venture Market, pending a completed audit by MaloneBailey LLP. Danner expressed excitement about the company’s growth potential, focusing on expanding both domestically and internationally. CB Scientific provides innovative cardiac monitoring solutions, emphasizing their commitment to transparency with future announcements.
CB Scientific Inc. (OTC PINK: CBSC) has initiated an independent financial audit with MaloneBailey, LLP to assess its financial statements as of March 31, 2021. This audit is crucial for the company's objective to uplist from OTC Pink to OTCQB, requiring PCAOB compliance. The audit will provide insights into CBSC's internal controls and offer a comprehensive overview of its financial health. The process is expected to conclude within eight weeks, ensuring transparency as the company aims to keep its investors informed of any developments.
CB Scientific Inc. (OTC PINK:CBSC) has launched the Heart Wellness Check-Up program in Bangkok, Thailand, through Mango Wellness and My Cardia Thailand. This new direct-to-consumer service enables remote cardiac monitoring via 26 pharmacies and clinics. The program allows customers to monitor heart health at home for 10 days using CBSC's my-Cam™ monitor, with data transmitted to a cloud-based portal. Several major hospitals are involved, and the initiative aims to address cardiac care during the COVID-19 pandemic.
CB Scientific (OTC PINK:CBSC) announced a consultancy agreement with the Dorchester Group, led by Robert H. Hesse, to enhance its financing and marketing strategies in the U.S. and Southeast Asia. The company is expanding its Remote Cardiac Monitoring services through a distributor, Mango Wellness, collaborating with three major Thai hospitals. This initiative aims to roll out CB Scientific's my-Cam remote monitoring products. The CEO emphasized that the partnership would assist in navigating regulatory approvals, especially for its my-Cam device in mainland China.
CB Scientific, Inc. (CBSC) announced a significant partnership with three major hospital chains in Thailand to implement Remote Cardiac Monitoring Services using their my-Cam device. This agreement follows successful trials with a diagnostic success rate of 85%. The hospitals involved are Ramkhamhaeng Hospital, Bangkok Hospital Nakon Ratchasima, and Bangpakok9 Hospital. The initiative, managed through Mango Wellness Co., Ltd., aims to enhance cardiac event monitoring and improve patient outcomes. Future expansions into government hospitals are also underway.
CB Scientific (OTC PINK:CBSC) announces its acquisition of Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) in New York, to enhance its position in the US Remote Patient Monitoring market. This strategic move aims to meet the rising demand for cardiac monitoring services, projected to grow at 18% annually from a 2019 revenue of $778M. The acquisition is expected to conclude by May 2021, aligning with CBSC's goal to address the health impacts of cardiovascular disease, which claims over 655,000 American lives yearly.